Type |
yearly
|
yearly
|
yearly
|
yearly
|
yearly
|
Date |
2023-12-31
|
2022-12-31
|
2021-12-31
|
2020-12-31
|
2019-12-31
|
Income before tax |
-276.11100M
|
-228.29000M
|
-340.09500M
|
-306.60500M
|
-290.96400M
|
Minority interest |
-
|
-
|
-
|
-
|
-
|
Net income |
-276.12600M
|
-228.30200M
|
-340.14100M
|
-306.62000M
|
-290.97600M
|
Selling general administrative |
50.91M
|
71.55M
|
78.80M
|
64.40M
|
79.58M
|
Selling and marketing expenses |
1.11M
|
-
|
-
|
-
|
-
|
Gross profit |
-0.31300M
|
49.01M
|
20.34M
|
-9.86700M
|
-8.10500M
|
Reconciled depreciation |
4.88M
|
5.65M
|
9.35M
|
8.33M
|
7.07M
|
Ebit |
-269.27600M
|
-280.51300M
|
-340.46200M
|
-309.05200M
|
-295.68100M
|
Ebitda |
-264.44700M
|
-330.75000M
|
-331.11700M
|
-300.72000M
|
-288.61100M
|
Depreciation and amortization |
4.83M
|
-50.23700M
|
9.35M
|
8.33M
|
7.07M
|
Non operating income net other |
-
|
52.22M
|
0.37M
|
2.45M
|
4.72M
|
Operating income |
-269.27600M
|
-280.51300M
|
-340.46200M
|
-309.05200M
|
-295.68100M
|
Other operating expenses |
277.85M
|
344.09M
|
360.80M
|
309.05M
|
295.68M
|
Interest expense |
5.29M
|
1.99M
|
9.71M
|
10.78M
|
11.79M
|
Tax provision |
0.00600M
|
0.01M
|
0.05M
|
0.01M
|
0.01M
|
Interest income |
4.80M
|
1.99M
|
0.37M
|
2.45M
|
4.72M
|
Net interest income |
0.94M
|
1.99M
|
0.37M
|
2.45M
|
4.72M
|
Extraordinary items |
-
|
-
|
-
|
-
|
-
|
Non recurring |
-
|
-
|
-
|
-
|
-
|
Other items |
-
|
-
|
-
|
-
|
-
|
Income tax expense |
0.01M
|
0.01M
|
0.05M
|
0.01M
|
0.01M
|
Total revenue |
8.57M
|
63.57M
|
20.34M
|
3.55M
|
0.00000M
|
Total operating expenses |
268.96M
|
344.09M
|
360.80M
|
309.05M
|
295.68M
|
Cost of revenue |
8.89M
|
14.57M
|
11.38M
|
9.87M
|
8.11M
|
Total other income expense net |
-6.83500M
|
52.22M
|
0.37M
|
2.45M
|
4.72M
|
Discontinued operations |
-
|
-
|
-
|
-
|
-
|
Net income from continuing ops |
-290.24800M
|
-228.30200M
|
-340.14100M
|
-306.62000M
|
-290.97600M
|
Net income applicable to common shares |
-
|
-228.30200M
|
-340.14100M
|
-306.62000M
|
-290.97600M
|
Preferred stock and other adjustments |
-
|
-
|
-
|
-
|
-
|